Precigen (PGEN) AI Stock Analysis

• Market Cap: $1.72B
• Dividend Yield: N/A
• Average Volume (3M): 4.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.91
• Revenue Growth: 59.20%
• EPS Growth: -155.65%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.06
• Shares Outstanding: 353,824,500
• 10 Day Avg. Volume: 3,150,122
• 30 Day Avg. Volume: 4,174,615
• PEG Ratio: -0.12
• Price to Book (P/B): 7.79
• Price to Sales (P/S): 76.40
• P/FCF Ratio: -3.91
• Enterprise Value/Market Cap: 0.58
• Enterprise Value/Revenue: 156.55
• Enterprise Value/Gross Profit: 681.14
• Enterprise Value/Ebitda: -4.04
• 1Y Price Target: $9.00
• Price Target Upside: 95.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: $5.00 ▲(8.46% Upside)

The score is held back primarily by weak financial performance: large ongoing losses, significant cash burn, and increased leverage despite improving revenue. Offsetting this, technicals are strong with price above major moving averages and positive momentum, and the latest earnings call was notably positive due to Papcemias approval and early commercialization progress with a stated path to cash flow breakeven by 2026. Valuation remains constrained by unprofitability and no dividend support.

Positive Factors

FDA Approval & Clinical Efficacy

Full FDA approval for Papcemias transforms Precigen from a pure R&D biotech into a commercial-stage company for RRP. As a first‑and‑only therapy with strong clinical results, it durablely reduces regulatory risk, enables revenue generation, and supports long-term commercial investment and market entry.

Rapid Commercial Traction & Payer Coverage

Quick institutional engagement and broad payer coverage indicate strong product adoption and reimbursement groundwork. These durable sales and access achievements increase likelihood of sustained uptake, predictable revenue streams, and faster scaling of commercial operations across regions and patient cohorts.

In‑house Manufacturing Capability

Owning an FDA‑inspected cGMP facility gives durable control over supply, quality, and unit economics as demand grows. This reduces reliance on external CDMOs, shortens time to supply scale‑up, and supports gross margin improvement and timely launches of follow-on indications or geographies.

Negative Factors

Large Ongoing Cash Burn

Sustained negative operating and free cash flow requires continued external financing or material profitable ramp from product sales. Over multiple quarters this elevates dilution or refinancing risk, constrains strategic flexibility, and pressures ability to fund R&D and commercial expansion without additional capital.

Materially Higher Leverage

A sharp increase in leverage materially raises fixed obligations and interest exposure, reducing balance sheet resilience. Higher debt limits strategic options, increases refinancing risk if revenues lag, and makes the company more vulnerable to operational setbacks during commercialization.

Persistent Unprofitability & Weak Operating Margins

Despite revenue growth, large negative operating margins show weak profit conversion and heavy cost structure. Sustained unprofitability means long runway required to reach self‑funding, and continued high SG&A for commercialization could pressure margins absent durable sales scale and efficiency gains.

Precigen Business Overview & Revenue Model

Company Description

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

How the Company Makes Money

Precigen generates revenue primarily through collaborations and partnerships with pharmaceutical companies, where it licenses its proprietary technologies and platforms for the development of therapeutic products. The company also engages in research and development agreements that provide upfront payments and potential milestone payments as projects progress. Additionally, Precigen may derive revenue from the commercialization of its own therapeutics, once they receive regulatory approval and enter the market. Key partnerships with established pharmaceutical companies and research institutions play a significant role in strengthening its revenue model, as these collaborations often include shared financial investments and resources, enhancing the company's ability to develop and bring new therapies to market.

Precigen Financial Statement Overview

Summary

Precigen's financial performance is weak, with negative net profit margins, negative equity, and poor cash flow generation. These factors indicate a high-risk financial profile with limited short-term improvement prospects.

Income Statement

Precigen's income statement reveals significant challenges. The company has been experiencing negative net profit margins, with the latest TTM data showing a net profit margin of -28.69%. Despite a slight revenue growth of 3.31% in the TTM period, the company has consistently reported negative EBIT and EBITDA margins, indicating ongoing operational inefficiencies. The gross profit margin has also been negative, reflecting cost management issues. Overall, the income statement suggests a struggling financial performance with limited profitability.

Balance Sheet

The balance sheet of Precigen highlights financial instability. The company has a negative stockholders' equity in the latest TTM period, indicating potential solvency issues. The debt-to-equity ratio is negative due to the negative equity, which is a significant red flag. Return on equity is also negative, reflecting the company's inability to generate profits from its equity base. These factors suggest a weak financial position with high risk.

Cash Flow

Precigen's cash flow statement shows some concerning trends. The company has been generating negative operating cash flow, with a TTM operating cash flow to net income ratio of -2.86, indicating poor cash generation relative to its net losses. Free cash flow growth is negative, and the free cash flow to net income ratio is slightly above 1, suggesting that while the company is managing to cover its net losses with free cash flow, the overall cash flow situation is precarious.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.31M	3.92M	6.22M	26.91M	14.27M	31.99M
Gross Profit	1.45M	-342.00K	106.00K	20.57M	-39.41M	-12.81M
EBITDA	-244.54M	-123.50M	-89.23M	-62.43M	-77.64M	-67.99M
Net Income	-246.87M	-126.23M	-95.90M	28.32M	-92.17M	-170.52M
Balance Sheet
Total Assets	171.26M	145.27M	151.04M	215.98M	359.86M	314.59M
Cash, Cash Equivalents and Short-Term Investments	121.14M	97.91M	62.85M	55.95M	108.66M	100.12M
Total Debt	98.19M	5.50M	7.10M	51.42M	190.07M	182.28M
Total Liabilities	129.40M	106.75M	32.55M	89.72M	252.51M	247.41M
Stockholders Equity	41.87M	38.51M	118.50M	126.26M	107.35M	67.17M
Cash Flow
Free Cash Flow	-75.62M	-76.76M	-68.47M	-69.97M	-63.02M	-84.55M
Operating Cash Flow	-72.61M	-68.17M	-66.93M	-65.05M	-55.77M	-77.02M
Investing Cash Flow	-106.77M	-20.71M	-3.09M	226.42M	-74.54M	27.78M
Financing Cash Flow	168.97M	110.58M	29.59M	-155.29M	121.19M	32.70M

Precigen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.61
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PGEN, the sentiment is Positive. The current price of 4.61 is above the 20-day moving average (MA) of 4.16, above the 50-day MA of 4.04, and above the 200-day MA of 2.73, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 59.93 is Neutral, neither overbought nor oversold. The STOCH value of 83.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PGEN.

Precigen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	71 Outperform	$953.78M	23.11	19.44%	―	14.77%	-58.90%
WVE	67 Neutral	$2.82B	-19.84	-86.51%	―	103.75%	33.84%
IMNM	63 Neutral	$2.20B	-6.92	-93.04%	―	-4.44%	63.58%
PRAX	60 Neutral	$7.37B	-22.81	-75.20%	―	364.98%	-25.33%
PGEN	59 Neutral	$1.72B	-3.29	-507.72%	―	59.20%	-155.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORIC	51 Neutral	$845.34M	-4.88	-39.73%	―	―	4.29%